ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years
Raëf Abdallah
Matched on OpenAlex author ID A5015546179. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 66
2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 8
- Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective ran… Co-author DOI 10.1016/j.canlet.2026.218745↗
- Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Co-author DOI 10.1093/oncolo/oyaf125↗
- Nutrition support in pancreatic cancer: An expert statement on practical implementation of French guidelines. First author DOI 10.1016/j.clinre.2023.102153↗
- FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
- BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2022.101880↗
- Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Co-author DOI 10.1038/s41416-021-01341-w↗
- Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. Co-author DOI 10.1016/j.ctrv.2020.102028↗
- How I treat pancreatic cancer. First author DOI 10.1136/esmoopen-2020-000818↗
Closest collaborators
The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Julien Taı̈eb · 8 shared papers, 2020–2026 · strength 1.30
- Paper Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of … DOI 10.1016/j.canlet.2026.218745↗
- Paper How I treat pancreatic cancer. DOI 10.1136/esmoopen-2020-000818↗
- Paper Nutrition support in pancreatic cancer: An expert statement on practical implementation of French guidelines. DOI 10.1016/j.clinre.2023.102153↗
- Jean‐Baptiste Bachet · 5 shared papers, 2020–2026 · strength 0.74
- Paper Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of … DOI 10.1016/j.canlet.2026.218745↗
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2022.101880↗
- Shulin Zhao · 3 shared papers, 2020–2026 · strength 0.48
- Paper Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of … DOI 10.1016/j.canlet.2026.218745↗
- Paper BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2022.101880↗
- Paper Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up:… DOI 10.1016/j.ctrv.2020.102028↗
- Pierre Laurent‐Puig · 3 shared papers, 2020–2026 · strength 0.48
- Paper Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of … DOI 10.1016/j.canlet.2026.218745↗
- Paper BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2022.101880↗
- Paper Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up:… DOI 10.1016/j.ctrv.2020.102028↗
- Laëtitia Dahan · 2 shared papers, 2025–2026 · strength 0.40
- Paper Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of … DOI 10.1016/j.canlet.2026.218745↗
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Jean–Marc Phelip · 2 shared papers, 2025–2026 · strength 0.40
- Paper Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of … DOI 10.1016/j.canlet.2026.218745↗
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Isabelle Trouilloud · 2 shared papers, 2025–2026 · strength 0.40
- Paper Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of … DOI 10.1016/j.canlet.2026.218745↗
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Jerome F. Cros · 2 shared papers, 2022–2026 · strength 0.37
- Lysiane Marthey · 2 shared papers, 2021–2025 · strength 0.26
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- Nicolas Williet · 2 shared papers, 2021–2025 · strength 0.26
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- David Tougeron · 2 shared papers, 2021–2025 · strength 0.26
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- Romain Coriat · 2 shared papers, 2021–2025 · strength 0.26
- Paper Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cance… DOI 10.1093/oncolo/oyaf125↗
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- Rémy Nicolle · 1 shared paper, 2026 · strength 0.24
- David Malka · 1 shared paper, 2026 · strength 0.24
- Louis de Mestier · 1 shared paper, 2026 · strength 0.24
- Baiyong Shen · 1 shared paper, 2026 · strength 0.24
- Olivier Bouché · 1 shared paper, 2026 · strength 0.24
- Léo Mas · 2 shared papers, 2020–2021 · strength 0.21
- Paper Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up:… DOI 10.1016/j.ctrv.2020.102028↗
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- Patrick Pessaux · 1 shared paper, 2023 · strength 0.20
- Cindy Neuzillet · 1 shared paper, 2023 · strength 0.20
- Alix Portal · 1 shared paper, 2025 · strength 0.16
- Franck Bonnetain · 1 shared paper, 2025 · strength 0.16
- Anne‐Laure Pointet · 1 shared paper, 2025 · strength 0.16
- Camille Evrard · 1 shared paper, 2025 · strength 0.16
- Émilie Soularue · 1 shared paper, 2025 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.